Trials / Completed
CompletedNCT00170846
ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients
Assessment of Everolimus in Addition to Calcineurin Inhibitors Reduction in Maintenance Renal Transplant Recipients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 394 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to evaluate whether the initiation of everolimus together with the reduction or discontinuation of calcineurin inhibitors (CNIs) will improve graft function in the maintenance of renal transplant recipients with renal impairment by reducing the progression of chronic allograft nephropathy. The development of atherosclerosis in the native arteries of the patients will also be explored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus (RAD001) | |
| DRUG | Calcineurin Inhibitors (CNI) | |
| DRUG | Mycophenolate acid (MPA)/Azathioprine (AZA) | |
| DRUG | Steroids |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2005-09-15
- Last updated
- 2015-01-27
- Results posted
- 2011-05-02
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00170846. Inclusion in this directory is not an endorsement.